Welcome to Campus Sanofi Malaysia

The United in Rare: Advancing LSDs Care across Asia event was held on the 22^nd to 23^rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

The programme brought together international and local experts to discuss the evolving understanding of Type 2 inflammation in atopic dermatitis, with a focus on IL-4 and IL-13, disease modification, and the importance of early intervention across different patient populations. 

Citation: Geba et al. Journal of Allergy and Clinical Immunology 2025;Vol.151: 756-766

Rare Disease Day raises awareness for the 300 million people worldwide living with a rare disease, along with their families and carers. Over 6,000 rare diseases are characterized by a wide range of conditions and symptoms that can vary not only between diseases but also among individuals with the same condition. Take the opportunity to support equitable access to diagnosis, treatment, healthcare, social support for those affected by rare diseases.

Join us for an insightful RSV Prevention event featuring expert presentations on the latest advances in respiratory syncytial virus prevention strategies for all infants. Gain valuable insights through four comprehensive video presentations, into systematic reviews of effectiveness data, healthcare system implementation approaches, global prevention strategies, and the significant impact of RSV prevention on reducing disease burden in pediatric populations.​

The United in Rare: Advancing LSDs Care across Asia event was held on the 22nd to 23rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.